Compare ARK Genomic Revolution ETF (ARKG) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs DuPont de Nemours Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.31, while DuPont de Nemours Inc trades at $134.02 (market cap $18.18B). The key difference: DuPont de Nemours Inc pays a 1.78% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, DuPont de Nemours Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | DD | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $154.59 |
52-Week Low | $23.09 | $87.72 |
Market Cap | — | $18.18B |
Enterprise Value | — | $20.65B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
DuPont (DD) trades at $134.68, down 0.08% on the day, with a bearish technical signal and negative net income margin of -0.42% for 2025. Recent earnings have consistently beaten estimates, but revenue declined to $6.85B in 2025 from $12.4B in 2024. The company faces a lawsuit over 'forever chemicals' and completed a 3:1 reverse stock split in June 2026, while maintaining dividend payments.
The stock presents a mixed outlook: strong analyst consensus with a $227.20 price target suggests significant upside, but persistent profitability challenges and legal risks weigh on fundamentals. Investment opportunity hinges on earnings turnaround and resolution of regulatory pressures, though current technical weakness and cash flow trends indicate near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
